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CCL28 is a mucosal chemokine that attracts eosinophils and T cells via the receptors CCR3 and CCR10. Consequently, it is a can-
didate mediator of the pathology associated with asthma. This study examined constitutive and induced expression of CCL28 by A549
human airway epithelial-like cells. Real-time RT-PCR and ELISA of cultured cells and supernatants revealed constitutive levels of
CCL28 expression to be low, whereas IL-1b and TNF-a, induced significantly increased expression. Observations from induced sputum
and human airway biopsies supported this. Signal transduction studies revealed that IL-1b and TNF-a stimulation induced NFjB phos-
phorylation in A549 cells, but antagonist inhibition of NFjB p50–p65 phosphorylation correlated with marked reduction of IL-1b or
TNF-a induced CCL28 expression. Together these studies imply a role for CCL28 in the orchestration of airway inflammation, and sug-
gest that CCL28 is one link between microbial insult and the exacerbation of pathologies such as asthma, through an NFjB-dependent
mechanism.
 2006 Elsevier Inc. All rights reserved.
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Chemokines are a family of 8–16 kDa proteins with
critical roles in immune cell trafficking, recruitment and
recirculation [1,2]. Their interaction with specific G-pro-
tein-coupled receptors (GPCRs) leads to paracrine, pleio-
tropic actions, resulting in the induction of inflammatory
infiltrates to tissues [3]. CC chemokines such as CCL2,
CCL3, CCL5 and CCL11/eotaxin attract lymphocytes,
eosinophils and monocytes [4–7]. These cells play a central
role in inflammation in the airways that leads to bronchial
hyperresponsiveness (BHR) and mucus hypersecretion,
seen during obstructive airway disorders that are reversible
(asthma) or irreversible (COPD) [8–11].
A novel CC chemokine, CCL28, also known as muco-
sae-associated epithelial chemokine (MEC), is expressed
in both murine and human mucosal tissues [1,12]. It0008-8749/$ - see front matter  2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.cellimm.2006.02.003
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E-mail address: bpmahon@nuim.ie (B.P. Mahon).displays chemotactic activity for eosinophils and both
CD4+ and CD8+ T cells through CCR3 and CCR10 recep-
tors [1,12,13]. Human CCL28 has a coding sequence of 373
nucleotide base pairs encoded by four exons separated by
introns of varying size [1,12]. There is 76% nucleic acid
identity between mouse and human sequences which results
in 83% similarity at the amino acid level [1,12]. Sequence
analysis has revealed CCL28 to be most similar to
CCL27/CTACK (cutaneous T-cell attracting chemokine).
CCL27 is constitutively expressed by keratinocytes but
has both a homeostatic and inflammatory role in the skin
[1,14–16]. It is not known if CCL28 plays similar roles at
mucosal sites.
The association of CCL28 with the eotaxin receptor
CCR3 [12], makes it a candidate chemokine for a role in
eosinophil infiltration at mucosal sites [17]. Recent evi-
dence has reappraised the eosinophil, which is now consid-
ered to play a critical role in the early events of airway
inflammation [18,19]; one of the dominant characteristics
of airway inflammation during respiratory distress [20].
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cytokines (IL-4, 5 and 13) [10], it is apparent that asthma is
more complex than an imbalance in the products of Th1
and Th2 cells [21]. Studies in knockout mice have revealed
a role for Th1 cytokines in exacerbating airway pathology
[22], and Th1-driving infections do not necessarily protect
but can exacerbate allergic asthma in murine models [23].
The mechanism that links pro-inflammatory infections
(often Th1-driven) and asthma (considered a Th2-driven
pathology) is poorly understood. However, it is likely that
monokines and cytokines such as IL-1b and TNF-a, pro-
duced early in the host pathogen encounter, determine
the chemokine profile that ultimately recruits Th2 cells
and eosinophils that mediate the pathology of allergic asth-
ma [24,25].
Recently, it has been demonstrated that IL-1a, but not
TNF-a, induced CCL28 transcription in a human colon epi-
thelial cell line [26]. The difference is unusual given that both
ligands share some signalling pathways and that IL-1a-med-
iated effects were shown to be dependent on the transcription
factorNFjB. Secreted IL-1b and TNF-a aremore central to
the events of inflammation and can initiate transcription of
chemokine genes via NFjB activation, albeit employing dif-
ferent cellular receptors and adaptormolecules [27,28], how-
ever there are unique signalling features to each cytokine
[27,29]. Binding of IL-1b to the IL-1 receptor 1 initiates the
arrangement of a signalling complex. The receptor accessory
protein, IL-1RacP associates with the adaptorsMYD88 and
TOLLIP [30]. Engagement of this signalling complex allows
recruitment of cellular IL-1 receptor-associated kinase
(IRAK) [31]. Phosphorylation of IRAK ultimately activates
the IjB kinase (IKK) complex. In contrast, TNF-a activates
NFjB via association of the TNF receptor associated death
domain (TRADD) adaptor with TRAF-2 and receptor
interacting protein (RIP) and this complex interacts with
IKK [29]. Both pathways converge on activated IKK which
phosphorylates the NFjB inhibitor, IjB [28]. Subsequent
polyubiquitination and degradation of phosphorylated
IjB, releases NFjB to translocate to the nucleus in dimer
form, and initiate gene transcription [27]. Five different pro-
tein sub-units, each containing conserved Rel homology
regions, constitute the NFjB family (p50, p52, p65/RelA,
RelB and c-Rel) [27]. Interaction between different sub-units
results in dimers that are active uponphosphorylation. Phos-
phorylated p50–p65 nuclear dimers are transcriptionally
active for genes related to inflammation, whereas other
dimers (e.g., p50–p50 or p50–RelB) typically act in transcrip-
tion of non-inflammatory genes or have a regulatory role
[28].
In the present study, the control of CCL28 in airway
inflammation was explored, and the link between the
NFjB signal transduction pathway and CCL28 expression
was examined. Both IL-1b and TNF-a induced NFjB-
dependent CCL28 expression at a high level, suggesting a
potential role for this chemokine in determining the quality
of airway inflammation following microbial insult. CCL28
may thus provide a mechanistic link between pro-inflam-matory, microbe-induced stimuli in the airways such as
IL-1b or TNF-a, and the subsequent exacerbation of pre-
existing pathologies such as asthma or COPD.
2. Materials and methods
2.1. Cell culture
A549 cells were cultured at 37 C without CO2 in
D-MEM:F12 (1:1) media including 15 mM HEPES, and
supplemented with 1% L-glutamine (Invitrogen, Paisley,
UK) and 5% heat inactivated FCS (Sigma–Aldrich, Dor-
set, UK).
2.2. Human-induced sputum and airway biopsy
Sputum samples were collected from 11 healthy, 1 asth-
matic and 1 subject with a respiratory infection following
stimulation with inhaled sodium chloride according to pre-
vious protocols [32]. Samples were processed by centrifuga-
tion and the supernatants stored at 20 C until required
for use. Biopsies were collected from two healthy donors,
six asthmatics and one subject with aspergillosis. Samples
were removed to RNA later (Ambion, Austin, USA) and
prepared for mRNA extraction. All subjects provided
informed consent, and the local research ethics committees
of both the collaborating institutions approved study
design.
2.3. In vitro stimulation of cells
A549 cells were cultured with a variety of recombinant
cytokines (R&D Systems, Oxford, UK and Immunotools,
Friesoythe, Germany) at concentrations previously deter-
mined as optimal for induction of inflammatory responses;
IL-4 and IL-5 (1 ng/ml), IL-13, SDF-1a, TGF-b1,
IL-12p40 and LPS (10 ng/ml) and GMCSF (50 ng/ml)
[4,33–39]. The pro-inflammatory cytokines, IL-1b or
TNF-a (R&D Systems, Oxford, UK), were introduced into
cultures either alone, in combination or following prior
exposure of the cell cultures to the NFjB antagonist pyr-
rolidine-dithiocarbamate (PDTC) (Sigma–Aldrich, Dorset,
UK). PDTC was used at concentrations described in figure
legends. For analysis of CCL28 mRNA expression, 5 · 105
cells were harvested after 6 h stimulation, whereas protein
determinations were from supernatants taken from cultures
at 24 h. These time points were selected after optimisation
studies (data not shown). No increase in apoptosis was
observed at either time point under any stimulation condi-
tion. For analysis of NFjB activation, nuclear extracts
were recovered from 8 · 106 cells, stimulated as described
above and cultured for 6 h.
2.4. Real-time RT-PCR quantification of CCL28 mRNA
Reverse transcription of total isolated RNA was carried
out as previously described [40] using Trizol (Molecular
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time PCR was carried out using a quantitative thermocy-
cler (MJ Research DNA Opticon, Massachusetts, USA)
in conjunction with the QuantiTect SYBR Green PCR
Kit (Qiagen, Crawley, UK). Each reaction mixture con-
tained 12.5 ll SYBR Green Master Mix and 0.4 pmol
appropriate primer. PCR primers for CCL28 were based
on the sequence of Pan et al. [12]; forward 5 0-TACTTCC
CATTGCCTCCAG-3 0 and reverse 5 0-ATGGTG
TTTCTTCCTGTGG-3 0. GAPDH primers were: forward
5 0-GGTGAAGGTCGGAGTCAACG-3 0 and reverse
5 0-C AAAGTTGTCATGGATGACC-3 0. Amplification
was performed by denaturation (95 C for 15 min at the
first cycle and subsequently for 45 s), annealing (60 C for
45 s, CCL28; or 55 C, GAPDH) and extension (72 C
for 1 min or 10 min in final cycle). Amplification of equal
concentrations of cDNA was performed over 36 cycles in
a reaction volume of 25 ll.
CCL28 mRNA concentration was expressed as fg/100 ng
cDNA or as a fold difference in CCL28 compared
to GAPDH mRNA. Relative quantification was deter-
mined by the formula 2DCt where DCt = (Ct CCL28 control –
Ct CCl28 stimulated) – (Ct GAPDH control – Ct GAPDH stimulated).
For this study, specific mRNA below 20 fg per 100 ng
cDNA is defined as low, whereas expression above this level
is termed high.
2.5. Detection of CCL28 protein
Measurement of CCL28 was carried out by sandwich-
type ELISA (R&D Systems, Oxford, UK), as previously
described [41]. Mouse anti-human CCL28 mAb (clone
62714) was used as capture antibody and biotinylated poly-
clonal goat anti-human CCL28 (R&D Systems, Oxford,
UK) was used to detect CCL28 in cell supernatants.
Human recombinant CCL28 protein (R&D Systems,
Oxford, UK) was titrated from 8000 pg/ml in doubling
dilutions and used to quantify CCL28 protein. For studies
of tissue culture supernatant, a CCL28 protein concentra-
tion below 100 pg/ml was defined as low, however, concen-
trations below 4.0 ng/ml were considered low for studies of
human sputum.
2.6. Nuclear extraction and measurement of NFjB
phosphorylation
Nuclear extracts were obtained from 8 · 106 control or
treated A549 cells after 6 h culture, using a commercial
kit according to the manufacturer’s instructions (Active
Motif, Rixensart, Belgium). Extracts were normalised for
protein content using the Biorad Protein Assay (Bio-
Rad Laboratories, California, USA), and subsequently
maintained at 80 C until required for use. Subsequently,
samples were assayed for the presence of phosphorylated
forms of NFjB p50, p52, p65, RelB and c-Rel sub-units
using the TransAm NFjB family transcription factor
assay kit (Active Motif). This ELISA-like system detectsonly phosphorylated nuclear forms of NFjB bound to a
fixed oligonucleotide specific for the NFjB consensus site.
The protocol, including suitable standards and controls,
was performed as recommended by the manufacturer.
2.7. Statistical analysis
Results were analysed by Student t-test or one-way
ANOVA with Bonferroni’s multiple comparison post-test
for significance as appropriate.
3. Results
3.1. CCL28 is expressed at low levels by human airway
epithelium-like cells and in induced human sputum
CCL28 may play a role in inflammatory airway disease.
Therefore, the expression of CCL28 by airway epithelium
was examined. Human airway epithelium-like A549 cells
were cultured for 6 h in the absence of any stimulus and
the isolated mRNA analysed. Using real-time quantitative
methods, these cells were found to constitutively express
CCL28 mRNA at low levels (Fig. 1). It is known that levels
of cytokine and chemokine mRNA do not always corre-
spond with protein expression. Therefore, CCL28 protein
secretion by A549 cells was determined by ELISA. Low,
but reproducibly positive, levels of CCL28 protein were
detected (Fig. 1C) suggesting that the constitutive presence
of mRNA is reflected in CCL28 protein expression by cul-
tured airway epithelium.AsA549 cells are a transformed cell
line, it could be argued that expression by these cells does not
reflect the scenario in vivo. Although this study was focused
on the mechanisms of CCL28 control, airway biopsy tissue
was sampled from normal healthy volunteers and from indi-
cator patients with inflammatory conditions such as asthma
or respiratory infection for confirmatory purposes. CCL28
mRNA extracted from human tissue was quantified by
real-time RT-PCR and was significantly elevated in an asth-
matic patient and an individual presenting with aspergillosis
compared to normal healthy human tissue (Fig. 2A). Again,
mRNA levels do not always correlate with protein expres-
sion, so CCL28 protein expression was examined ex vivo.
Induced sputum was collected from 11 healthy volunteers
and analysed by ELISA for the presence of CCL28 protein.
Fig. 2B shows that sputum contained low levels of CCL28
protein a (1.7 ng/ml ± 0.23). Interestingly, the CCL28 pro-
tein content of sputum induced from an asthmatic patient
prior to anti-inflammatory treatment was much higher
(4.0 ng/ml ± 0.26, p < 0.05) as was sputum induced from
an individualwith anunidentifiedbacterial respiratory infec-
tion (8.0 ng/ml ± 0.73, p < 0.001). Although the human
study can only be considered indicative, taken together these
data are consistent with CCL28 being constitutively
expressed at low levels by healthy human airway epithelium
but suggest that this is increased during respiratory inflam-
mation, supporting both a homeostatic and inflammatory
role for CCL28 at this mucosal site.
Fig. 1. IL-1b and TNF-a induce upregulation of constitutive CCL28 expression in vitro. A549 airway epithelial-like cells were cultured in the absence or
presence of IL-1b (10 ng/ml) or TNF-a (100 ng/ml) for 6 h. CCL28 and GAPDH mRNA were amplified and quantified by real-time RT-PCR. Data are
expressed in absolute quantities per 100 ng of cDNA (A) or normalised to GAPDH and expressed as a fold increase relative to control (B); CCL28 protein
present in culture supernatant after 24 h was measured by ELISA (C and D). mRNA quantities are expressed as mean (±SEM) from duplicate
determinations of a representative experiment (performed three times). Protein levels represent mean concentration (±SEM) of triplicate determinations,
from a representative experiment (performed at least three times), *p < 0.05, **p < 0.01.
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expression in vitro
IL-1b and TNF-a can both be present in the airways
during infections that are known to exacerbate asthma
[23,42]. The presence of CCL28 in the respiratory tract,
its association with the receptors CCR3 and CCR10
[1,12,17], and the indicative data from inflamed tissue,
point to a role for the chemokine during airway inflamma-
tion. To further elucidate the effects of an inflammatory
environment on CCL28 expression, A549 cells were
exposed to a variety of inflammatory stimulants and ana-
lysed for the presence of mRNA and secreted protein as
described above. Contrary to observations from colon
cells, exposure to IL-1b or TNF-a caused a significant
increase in CCL28 mRNA and protein relative to non-
treated cells (Figs. 1A–C) although the increase in mRNA
after TNF-a stimulation was less dramatic than with IL-1b.
Increased CCL28 mRNA and protein induction was
dependent upon the degree of stimulation and concentra-
tions of IL-1b or TNF-a above 0.1 or 1.0 ng/ml, respective-
ly, were required to achieve significance (results not
shown). No significant apoptosis was observed within these
cultures. Combined stimulation of A549 cells with IL-1b
and TNF-a, enhanced CCL28 protein expression above
that seen with either cytokine alone (Fig. 1) but only at
TNF-a concentrations below 1 ng/ml (Fig. 1). Interesting-
ly, other factors associated with bronchial inflammation,
asthma or eotaxin induction did not significantly increase
either CCL28 mRNA or protein expression above controls
(Table 1).3.3. IL-1b and TNF-a induce phosphorylation of NFjB
in vitro
The NFjB signal transduction pathway is involved
in both IL-1b- and TNF-a-mediated induction of che-
mokines [43]. Recently it has been demonstrated that
antagonists of NFjB successfully inhibit IL-1a induced
CCL28 transcription in a human colon epithelial cell
line [26]. Since IL-1b and TNF-a are also known to
signal via the NFjB pathway, cytokine induction of
transcription factor phosphorylation was assessed in
A549 cells. An ELISA-like assay was used to analyse
the phosphorylation of NFjB sub-units, p50, p52,
p65, RelB, and c-Rel, isolated from cells cultured in
the presence or absence of either IL-1b or TNF-a.
Following 6 h stimulation, A549 cells were removed
from culture and nuclear extracts isolated. Fig. 3
shows that IL-1b significantly increased phosphoryla-
tion of NFjB p50 and p65 relative to control cells
(p < 0.01) as detected in nuclear extracts (Figs. 3A
and B). Significant but smaller increases were observed
for the phosphorylated p52 and RelB sub-units, while
no change was detected in c-Rel phosphorylation in
nuclear extracts (results not shown). Exposure to
TNF-a (10 ng/ml) increased phosphorylation of p50
(p < 0.01) and p65 (p < 0.01) (Figs. 3C and D) with
no significant effect on the other components exam-
ined. Thus although there may be differences in scale
and concentration, both cytokines are effective in
inducing transcriptionally active NFjB p50–p65 in
A549 cells.
Fig. 2. CCL28 is expressed in human airway tissue and induced sputum.
CCL28 mRNA extracted from normal or inflamed human airway, was
quantified by real-time RT-PCR and data expressed in absolute quantities
per 100 ng cDNA (A). Values are expressed as means (±SEM) from
triplicate (n = 3) determinations. mRNA from inflamed airway tissue
shows significantly higher CCL28 expression than normal healthy tissue,
*p < 0.05, **p < 0.01. Induced sputum from 11 healthy non-smoking
control volunteers were processed and analysed by ELISA for CCL28
protein content (B). Each point represents the mean CCL28 concentration
determined in triplicate for each patient. The solid line represents the mean
CCL28 concentration detected overall.
Table 1
Inflammatory mediators associated with infection or asthma do not
upregulate CCL28 expression from airway epithelial-like cells
Stimulusa Significant induction above
background expressionb
mRNA Protein
Medium  
CCL28  
IL-4  
IL-5  
IL-13  
IL-4 + IL-5  
IL-4 + IL-13  
IL-5 + IL-13  
IL-4 + IL-5 + IL-13  
SDF-1  
TGF-b1  
GMCSF  
IL-12p40  
LPS  
TNF-a + +
IL-1b + +
TNF-a + IL-1b + +
a Human airway epithelial-like A549 cells were cultured in the presence
or absence of inflammatory mediators at concentrations and times given in
methods; IL-1b (10 ng/ml) is included as a positive control.
b Expression of CCL28 was compared to non-stimulated cells by
quantitative real-time PCR (mRNA) following 6 h culture, or by CCL28
specific ELISA (protein) on culture supernatant after 24 h.
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in vitro
It was possible that IL-1b or TNF-a induced CCL28
by a pathway independent of NFjB activation. To con-
firm the involvement of the NFjB signal transduction
cascade in cytokine-mediated CCL28 induction, A549
cells were treated with the NFjB inhibitor, PDTC,
30 min prior to IL-1b or TNF-a exposure. Nuclear
extracts of cells pre-treated with PDTC, displayed
significantly lower levels of phosphorylated NFjB p50
and p65 relative to cells treated with IL-1b (p < 0.001,
Figs. 4A and B) or TNF-a alone (p < 0.001, Figs. 4C
and D). PDTC treated A549 cells also displayed signifi-
cantly reduced CCL28 mRNA, despite stimulation with
IL-1b or TNF-a (p < 0.001 and p < 0.05, respectively)
(Fig. 5). Levels of secreted CCL28 protein were alsosignificantly reduced following pre-treatment with PDTC,
when compared to cytokine treatment alone (Figs. 5C and
F). These studies confirm that IL-1b induces high levels of
CCL28 expression in A549 cells via an NFjB-dependent
pathway and demonstrates that TNF-a behaves in a sim-
ilar manner to IL-1b in these cells.
4. Discussion
We report the constitutive expression of CCL28 mRNA
and protein by the A549 human airway epithelial-like cell
line. Ex vivo, we have shown low levels of CCL28 mRNA
to be expressed in healthy, non-asthmatic human control
airway biopsy tissue, while induced sputum from healthy
human volunteers also contained CCL28 protein at low
levels. Biopsy tissue and induced sputum from sample
patients with asthma or respiratory infection presented
higher levels of CCL28. Unstimulated airway epithelium-
like A549 cells expressed constitutive but low levels of
CCL28 mRNA and protein. However, exposure to the
pro-inflammatory cytokines IL-1b or TNF-a significantly
increased CCL28 expression, whereas IL-4, IL-5 and IL-
13 did not. TNF-a enhanced IL-1b induction of CCL28
protein but this effect was concentration dependent. Both
cytokines induced phosphorylation of NFjB p50 and p65
in A549 cells and this correlated with increased CCL28
expression. Inhibition of NFjB p50–p65 activation by an
antagonist correlated with reduced cytokine-mediated
CCL28 expression confirming that CCL28 induction is
NFjB-dependent.
Fig. 3. IL-1b (A and B) and TNF-a (C and D) induce phosphorylation of NFjB sub-units in A549 cells. Exposure to IL-1b or TNF-a (10 ng/ml) induced
significant activation of p50 (A and C) and p65 (B and D). Phosphorylated NFjB components were measured in nuclear extracts by phospho-ELISA
following exposure of A549 cells to cytokine or from extracts of non-stimulated control cells (0). Nuclear extract from RAJI cells (+) was used as a positive
control for comparison against background optical density (). Absorbance values are expressed as mean optical density at 450 nm (±SEM) for duplicate
samples from representative experiments performed three times. Statistical significance was measured relative to non-stimulated controls (0), **p < 0.01.
Fig. 4. IL-1b (A and B) and TNF-a (C and D) phosphorylation of p50 and p65 is inhibited by an NFjB antagonist. Cytokine-induced phosphorylation of
p50 (A and C) and p65 (B and D) was measured by ELISA following exposure of A549 cells to nuclear extracts from non-stimulated control cells (0), or
from cells cultured with combinations of the NFjB antagonist PDTC (100 lM) and /or IL-1b (10 ng/ml) or TNF-a (10 ng/ml). A nuclear extract from
RAJI cells (+) was used as a positive control for comparison against background optical density (). Absorbance values are expressed as mean optical
density at 450 nm (±SEM) for duplicate samples from representative experiments performed at least three times. *** represents significant reduction from
stimulated cells (p < 0.001 in each case).
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homeostatic chemokine with inflammatory roles in the gut,
little is known of its regulation or involvement in mucosalimmunity in the airways [44,45]. Similar to CCL25, CCL28
is capable of enhancing adhesion of IgA+ antibody secret-
ing cells in the intestine, allowing increased extravasation
Fig. 5. Reduction of CCL28 expression following NFjB inhibition in vitro. A549 cells were exposed to the NFjB antagonist, PDTC (100 lM) 30 min
prior to treatment for 6 h with 10 ng/ml IL-1b or 100 ng/ml TNF-a. Results were compared to cells treated with cytokine alone. CCL28 and GAPDH
mRNA expression were measured by real-time quantitative PCR. Data were expressed in absolute quantities per 100 ng of cDNA (A and B) or normalised
to GAPDH and expressed as a fold increase relative to control (C and D). CCL28 protein present in supernatant culture fluid was measured by ELISA
(E and F). Results are from representative experiments, performed three times. Data are expressed as means (±SEM) for duplicate (mRNA) or triplicate
(protein) samples.
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more, CCL28 present in mammary tissue plays a role in
accumulation of IgA plasma cells during lactation and pro-
motes the transfer of IgA-mediated immunity to the neo-
nate [48]. CCL28 is also a chemoattractant for CLA+ T
cells [1,12]. Thus, CCL28 is likely to play an important role
in governing homeostasis and inflammation at mucosal
sites. The constitutive expression of CCL28 mRNA and
protein by human airway-derived A549 cells observed here
is consistent with experiments by Pan et al., showing
CCL28 mRNA in human bronchial epithelial cell lines
[12]. Recently published work by John and colleagues
and also from our laboratory, support a role for CCL28
in murine airway inflammation with low constitutive levels
of CCL28 mRNA [17,39]. Our detection of CCL28 in
healthy human airway tissue (mRNA) and in sputum from
healthy volunteers supports a role for CCL28 in the
homeostatic and innate mechanisms operating in human
respiratory tract. The full nature of this role is yet to be elu-
cidated, but as CCL28 is known to exhibit anti-microbial
activity [41], it is likely that the homeostatic function ofCCL28 in sputum is in part to provide an innate or ‘‘front-
line’’ immune response at the mucosal surfaces of the
airways.
The similarity between CCL28 and the keratinocyte
CCR10 ligand CCL27 [1], suggested that there may be an
additional inflammatory role for this chemokine in the air-
ways. In the present study, we show that a variety of
inflammatory mediators including IL-4, IL-5 and IL-13
do not induce high levels of CCL28 expression, nor does
CCL28 act in an autocrine fashion (Table 1). Taken togeth-
er with data suggesting that CCL28 is chemotactic for
eosinophils [17,46] this suggests that CCL28 is acting earli-
er in airway inflammation than these mediators. This is
consistent with the observation that CCL28 is produced
by airway epithelium, acting not simply as an inert barrier,
but as an important signalling cell in the early events of air-
way inflammation [21]. We show that IL-1b and TNF-a are
capable of upregulating CCL28 expression from human
airway epithelial cells. These cytokines are produced by cir-
culating macrophages and monocytes following exposure
to microbial stimuli, and are associated with bacterial
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and colleagues have demonstrated that IL-1a alone or in
combination with a variety of microbial products, upregu-
lated CCL28 in human colon epithelial cell lines [26]. While
surface expressed IL-1a shares some functions with secret-
ed IL-1b, the latter has a more defined role in airway
pathology. It has been implicated in asthma through induc-
tion of the CXC chemokine RANTES [10,49]. IL-1b can
enhance eosinophil trafficking to the lung by increasing
the expression of adhesion molecules on respiratory endo-
thelial cells and TNF-a acts in similar fashion [49]. Both
cytokines also upregulate the expression of a variety of
genes that contribute to the alteration of airway smooth
muscle during the asthmatic response [50,51]. Thus, these
data support a role for IL-1b or TNF-a produced as a
result of microbial insult inducing high levels of CCL28
and exacerbating asthma. We have observed elevated
CCL28 expression in inflamed human airway tissue when
compared to normal healthy control biopsy tissue. Also
induced sputum from representative asthmatic or infected
patients contained higher quantities of CCL28 protein than
control volunteers. These data are merely indicative and to
support the present in vitro study but similar observations
have been made in animal models of asthma, where consti-
tutive CCL28 is upregulated following allergen challenge
[17,39].
Our observation that TNF-a can upregulate CCL28 in a
human airway epithelial cell line is consistent with previous
work from our laboratory demonstrating that TNF-a
increases CCL28 mRNA from the murine airway epithelial
cell line, MLE12 [39]. However, it is in contrast to the
observations of Ogawa using colon derived human cells
[26]. One possibility was that CCL28 in airway epithelium
cells was regulated in a different manner to that in intestinal
epithelium, suggestive of a functionally distinct, tissue-spe-
cific role for the chemokine. However, our demonstration
that both IL-1b and TNF-a induce expression through
an NFjB-dependent pathway would argue against this.
Nonetheless, we did observe that TNF-a-mediated induc-
tion of CCL28 tended to be more sensitive to concentration
and timing effects and typically resulted in lower chemo-
kine production when compared to IL-1b.
IL-1b and TNF-a can both initiate NFjB activation
through various signalling pathways to allow phosphoryla-
tion of Rel protein species and the formation of active tran-
scription factor dimers within the nucleus [43]. In this
study, we find that IL-1b and TNF-a activate similar pat-
terns of NFjB phosphorylation, predominantly the p50–
p65 heterodimer. This data is the first to show TNF-a
and IL-1b regulation of human CCL28 and to show that
this pathway is dependent on p50–p65 activation. Howev-
er, inhibition of NFjB phosphorylation did not result in
complete ablation of cytokine-induced CCL28 mRNA or
protein (Fig. 5). Whilst low-level constitutive production
may account for some residual expression, it also suggests
that other signalling pathways contribute to CCL28 regula-
tion. LPS was not capable of inducing epithelial produc-tion of CCL28 in this system, however, we have
previously shown that oncostatin-M, can induce murine
CCL28 from airway epithelial cells and it is possible that
IL-6-like cytokines or other inflammatory mediators
induce CCL28 via NFjB-independent pathways in
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